Loading field map
Biomaterials is the study and engineering of materials intended to interface with biological systems, whether for medical diagnosis, therapy, or the fundamental understanding of how living tissue responds to non-living matter. The field is defined less by a single class of substance than by a purpose: a biomaterial is any material—natural or synthetic, solid or gel, degradable or permanent—that is designed to function in contact with living tissue, cells, or biological fluids. This working definition, formalized in the late twentieth century, distinguishes the modern discipline from the much older, unreflective use of materials in medicine. A metal pin used to fix a bone fracture is a biomaterial in the modern sense only when its composition, surface chemistry, and degradation behavior have been deliberately engineered to elicit a predictable biological response.
The core intellectual problem of biomaterials is the interface. Living systems are exquisitely sensitive to the chemical and physical character of surfaces, and they respond to an implanted material through a cascade of events: protein adsorption, immune cell recruitment, inflammation, and either integration or rejection. The central question is therefore how to design a material that performs a mechanical or structural function while provoking a desired—or at least tolerable—biological reaction. This question branches into several enduring sub-questions. How does the body recognize a material as foreign, and can that recognition be redirected? How can a material be made to degrade at a controlled rate while its degradation products are safely metabolized or excreted? How can a material mimic the mechanical properties of native tissue—bone, cartilage, blood vessels—without triggering a mismatch that leads to failure? And how can materials be designed to actively guide biological processes, such as cell adhesion, migration, or differentiation, rather than merely passively coexist with them?
The stakes are high because the failure modes are unforgiving. An implanted device that triggers a chronic inflammatory response may be encapsulated in fibrous scar tissue, losing its function. A blood-contacting material that promotes clot formation can cause stroke or thrombosis. A degradable scaffold that resorbs too quickly collapses before new tissue has formed; one that resorbs too slowly remains as a permanent foreign body. Beyond implants, biomaterials underpin drug delivery systems, tissue engineering scaffolds, diagnostic sensors, and the growing field of biofabrication. The field thus carries a dual responsibility: to advance fundamental understanding of material–biology interactions and to translate that understanding into devices that are safe, effective, and manufacturable.
The use of materials in the body is ancient—gold wire for dental repair, iron and bronze for bone fixation, and various natural substances for wound closure appear in historical records across many cultures. But these were empirical practices, not a science. The modern field emerged in the mid-twentieth century, driven by wartime and postwar surgical needs, the development of synthetic polymers, and a growing recognition that material choice could determine surgical success. Early implants were often borrowed from industrial or consumer applications: poly(methyl methacrylate) (PMMA) used for aircraft canopies became a material for bone cement and intraocular lenses; silicone rubber developed for other purposes found use in breast implants and hydrocephalus shunts; Teflon, a nonstick coating, was repurposed for vascular grafts.
The turning point came when clinicians and engineers realized that the body's response to these materials was not a simple matter of inertness. In the 1960s and 1970s, researchers began systematically studying the tissue reaction to implanted materials, establishing the concept of biocompatibility—not as an intrinsic property of a material, but as the ability of a material to perform its function with an appropriate host response in a specific application. This shift from "inert" to "appropriate" was conceptual and remains foundational. A material that is biocompatible for a bone screw may be entirely unsuitable for a heart valve, because the required host response differs.
The 1980s and 1990s saw the rise of biodegradable materials, particularly polyesters like polylactic acid and polyglycolic acid, which could be engineered to degrade over weeks to months. This enabled the concept of tissue engineering: a temporary scaffold that guides the body to regenerate its own tissue, then disappears. The same period saw the development of bioactive ceramics and glasses that bond directly to bone, and the first generation of surface modifications designed to control protein adsorption and cell adhesion. The field has since expanded to include hydrogels that mimic soft tissue, materials that respond to biological stimuli, and the use of biological molecules—growth factors, peptides, DNA—as integral components of material design.
The field is not organized into a single sequence of rival schools, but rather into several coexisting research traditions that address different aspects of the material–biology interface. These traditions overlap, borrow from one another, and often combine in a single device.
The oldest modern approach sought materials that would provoke the least possible biological response. The assumption was that the body's reaction to a foreign body is fundamentally harmful, so the best material is one that is chemically stable, mechanically robust, and as invisible to the immune system as possible. This tradition produced the classic implant metals—stainless steel, cobalt-chromium alloys, titanium and its alloys—as well as alumina and zirconia ceramics, and stable polymers like ultra-high-molecular-weight polyethylene. Titanium, in particular, became a workhorse because it forms a thin, stable oxide layer that resists corrosion and, as later research showed, actually integrates with bone in a process called osseointegration.
The limits of this approach became clear over time. No material is truly inert; all provoke some response, and the fibrous capsule that forms around a "silent" implant can be as problematic as an overt inflammatory reaction. Moreover, inertness is a passive property. It does not help the body heal, integrate the device, or regenerate tissue. The tradition remains influential, however, because mechanical reliability and chemical stability are still essential for load-bearing implants like hip and knee replacements, and because the principles of corrosion resistance and fatigue life remain central to implant design.
A second tradition, emerging in the 1970s, rejected the goal of invisibility in favor of deliberate interaction. Bioactive materials are designed to elicit a specific, beneficial biological response. The most important examples are the calcium phosphate ceramics and bioactive glasses, which release calcium and phosphate ions that stimulate bone-forming cells and bond directly to bone tissue. Bioglass, discovered by Larry Hench in 1969, was the first material shown to form a stable bond with living bone through a sequence of surface reactions that produce a hydroxyapatite layer similar to the mineral phase of bone. This discovery demonstrated that a material could actively participate in the healing process rather than merely tolerate it.
The bioactive tradition expanded to include surface modifications of otherwise inert materials—for example, coating a titanium implant with hydroxyapatite to encourage bone bonding—and, more recently, materials that release growth factors, antimicrobial agents, or other biologically active molecules. The organizing assumption is that the material should not be a passive bystander but an active participant in tissue repair. The limitation is that bioactivity is application-specific: a material that promotes bone growth is not useful for a blood-contacting device, where the goal might be to prevent cell adhesion. Bioactive approaches also raise the challenge of controlling the dose and duration of biological signals, since an overactive response can be as harmful as none.
A third tradition focuses on materials that are designed to disappear. The rationale is that a permanent implant is a permanent compromise: it may fail mechanically over time, it may cause late inflammation, and it leaves no room for the body to regenerate its own tissue. Degradable materials—primarily synthetic polyesters, natural polymers like collagen and chitosan, and certain ceramics—are engineered to lose mechanical strength and mass at a controlled rate while their degradation products are metabolized or excreted. This approach is essential to tissue engineering, where a scaffold must support cell growth and new tissue formation, then resorb as the new tissue takes over.
The central challenge is matching degradation kinetics to tissue healing kinetics. Bone heals over months; nerve regeneration takes longer; a drug delivery system might need to release its payload over days or years. Degradation rate depends on polymer chemistry, molecular weight, crystallinity, and the local biological environment, which varies by tissue and patient. The field has developed sophisticated models of degradation, but predicting in vivo behavior from in vitro tests remains difficult. A further complication is that degradation products are not always benign; acidic byproducts from polyester degradation can cause local inflammation if they accumulate faster than the tissue can clear them.
A fourth tradition addresses the special demands of soft tissue. Hydrogels—crosslinked polymer networks that swell with water—can be formulated to mimic the mechanical properties of cartilage, brain tissue, or the extracellular matrix. Their high water content allows diffusion of nutrients and waste, and their chemistry can be tuned to present biological signals that guide cell behavior. Hydrogels are used in contact lenses, wound dressings, drug delivery depots, and as scaffolds for soft tissue regeneration. They are also the primary material class for cell encapsulation, where living cells are enclosed in a gel that protects them from immune attack while allowing exchange of oxygen, nutrients, and therapeutic proteins.
The limitation of hydrogels is mechanical: most are too weak to bear load, and their high water content makes them prone to dehydration and degradation. Recent work has focused on strengthening hydrogels through double networks, nanocomposite reinforcement, or chemical crosslinking, but the trade-off between mechanical robustness and biological compatibility remains a central tension. Hydrogels also illustrate the importance of physical cues—stiffness, porosity, topography—in addition to chemical signals. Cells sense and respond to the mechanical properties of their surroundings, and a hydrogel that is too stiff or too soft can alter cell behavior in unintended ways.
A fifth tradition treats the surface, rather than the bulk, as the primary site of biological interaction. Since proteins adsorb to any material within milliseconds of contact with blood or tissue fluid, and since cells interact with this protein layer rather than with the material itself, controlling protein adsorption is a powerful lever. Surface engineering includes chemical modifications (grafting polymer brushes, attaching peptides or antibodies), physical modifications (roughening, patterning, coating), and the use of self-assembled monolayers to create well-defined model surfaces for studying cell behavior.
This tradition has produced important insights into how surface chemistry, charge, wettability, and topography influence protein conformation and cell adhesion. It has also produced practical technologies: non-fouling coatings that resist protein adsorption for blood-contacting devices, antimicrobial surfaces that kill bacteria on contact, and patterned surfaces that guide cell alignment for nerve or muscle regeneration. The limitation is that surface modifications can degrade over time, and the complexity of the biological environment—hundreds of proteins competing for surface sites—makes it difficult to predict performance from simple model experiments.
These traditions are not mutually exclusive, and most modern biomaterials combine elements of several. A titanium hip implant may have a bioactive hydroxyapatite coating to encourage bone bonding, a surface texture to promote mechanical interlock, and a bulk composition chosen for fatigue resistance. A tissue engineering scaffold may be a degradable polyester that releases growth factors (bioactive), has a hydrogel component to fill irregular defects, and is surface-modified to present cell-adhesion peptides. The field's practical work is largely about balancing these considerations: how much bioactivity is appropriate, how fast degradation should proceed, whether the surface or the bulk should dominate the design.
There are also genuine disagreements. The inert tradition and the bioactive tradition embody different philosophies about the body's response to materials—one viewing it as a problem to be minimized, the other as an opportunity to be exploited. The degradable tradition challenges the assumption that implants must be permanent, while the hydrogel tradition challenges the assumption that materials must be dry and stiff. These are not rival paradigms in the sense of mutually exclusive worldviews; they are complementary strategies that address different clinical problems. A researcher who works on permanent metal implants and a researcher who works on injectable hydrogels share the same fundamental questions about protein adsorption, immune response, and biocompatibility, even though their materials and methods differ.
The contemporary field is characterized by increasing convergence with cell biology, molecular biology, and manufacturing technology. The traditional focus on bulk material properties has given way to a more nuanced understanding of the material as a signaling platform—a way to present biochemical and biophysical cues to cells in a controlled spatial and temporal pattern. This is evident in the rise of materials that respond to biological stimuli: hydrogels that release drugs in response to inflammation, scaffolds that degrade faster in response to mechanical loading, and materials that change stiffness in response to enzymatic activity.
Another major development is the use of biological materials themselves—decellularized tissue, extracellular matrix proteins, and living cells—as components of biomaterial systems. These materials offer a level of biochemical complexity that synthetic materials cannot match, but they also raise challenges of batch-to-batch variability, immunogenicity, and regulatory approval. The distinction between a biomaterial and a biological therapeutic has become blurred, particularly in tissue engineering and regenerative medicine, where a scaffold, a growth factor, and cells may be combined into a single product.
Additive manufacturing, or three-dimensional printing, has transformed the field's ability to create patient-specific implants and scaffolds with controlled architecture. This has driven interest in printable biomaterials—materials that can be extruded, photopolymerized, or otherwise processed into complex shapes while maintaining their biological function. The challenge is that the processing conditions required for printing (heat, shear, ultraviolet light) can damage biological molecules or create inhomogeneities in the material.
The field also faces persistent translational challenges. Many biomaterials that perform well in animal models fail in human trials, often because the biological response is more variable in humans or because the mechanical demands of human use are greater. Regulatory pathways for combination products—materials that include drugs or cells—are complex and evolving. And the economic realities of device development mean that many promising materials never reach clinical use. These challenges are not failures of the field's science but rather the context in which its science operates.
The most durable contribution of biomaterials as a discipline may be its insistence on the interface as a site of design. The field has moved from asking "What material is least harmful?" to asking "What material can do the most good?"—and in doing so, it has created a framework for thinking about materials not as inert objects but as participants in biological processes. That framework, built on decades of careful study of protein adsorption, cell adhesion, inflammation, and tissue integration, remains the foundation on which new materials and new applications are built.